Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated liposomal doxorubicin + carboplatin vs paclitaxel + carboplatin in late-relapse epithelial ovarian cancer
2004-004456-39Phase 3Completed
- Sponsor
- ARCAGY
- Start
- Jul 2005
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in epithelial ovarian cancer (EOC) comparing Caelyx + carboplatin with Paclitaxel + carboplatin (2 arms). Primary endpoint: Progression-free survival. Started Jul 2005; status: completed.
02
Drugs
pegylated liposomal doxorubicincarboplatinpaclitaxel
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2004-004456-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004456-39.